PCV chemotherapy

What it is

PCV is a combination chemotherapy regimen — consisting of three drugs (procarbazine, lomustine, and vincristine) — used particularly for oligodendrogliomas and some other gliomas. It is often given after radiation and can meaningfully improve outcomes in certain tumors.

Understanding PCV chemotherapy

PCV combines three drugs that work together against tumor cells. It has an important role in treating oligodendrogliomas (IDH-mutant, 1p/19q-codeleted tumors), which are particularly responsive to chemotherapy: studies have shown that adding PCV to radiation can substantially extend survival in these tumors, making radiation-plus-PCV a key option for them. PCV is also used in some astrocytomas and other gliomas in certain situations. Because it is a multi-drug regimen, PCV has a broader range of potential side effects than single-agent temozolomide (the drugs affect blood counts and can have other effects), which are monitored and managed. The choice between PCV and temozolomide-based approaches depends on the tumor type, molecular features, and individual factors, decided with the oncology team. PCV illustrates how certain gliomas are especially chemo-responsive. Understanding PCV chemotherapy in gliomas clarifies a combination regimen valuable for oligodendrogliomas and some other tumors.

Why it matters

Understanding PCV chemotherapy helps patients and families see a combination regimen especially valuable for oligodendrogliomas — often given after radiation — that can meaningfully improve outcomes in these chemo-responsive tumors.